Neurocrine Biosciences Falls on Corticotropin Data (NBIX)

Neurocrine Biosciences Falls on Corticotropin Data (NBIX) Shares of Neurocrine Biosciences, Inc. NBIX are falling in the after-hours by over 7.00%, currently trading at $5.80. The stock closed Tuesdayssion at $6.25. The company issued a press release that sayd its trial on Corticotropin did not meet its primary endpoint. The company said that the study did not demonstrate a treatment effect compared to placebo. This was a Phase II clinical trial. Neurocrine Biosciences, Inc., incorporated in January 1992, is engaged in developing, discovering and commercializing drugs for the treatment of neurological and endocrine-related diseases and disorders. During the year ended December 31, 2009, the company had eight programs in various stages of research and development, including five programs in clinical development.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: FDAAfter-Hours CenterMoversBiotechnologyHealth Care
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!